AYALA PHARMACEUTICALS INC (AYLA)

US05465V1089 - Common Stock

0.5036  +0.03 (+5.84%)

Fundamental Rating

2

AYLA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. The financial health of AYLA is average, but there are quite some concerns on its profitability. AYLA does not seem to be growing, but still is valued expensively.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

AYLA had negative earnings in the past year.
AYLA had a negative operating cash flow in the past year.

1.2 Ratios

The profitability ratios for AYLA are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

AYLA's Gross Margin of 5.19% is fine compared to the rest of the industry. AYLA outperforms 74.49% of its industry peers.
The Profit Margin and Operating Margin are not available for AYLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 5.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

AYLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AYLA has been increased compared to 1 year ago.
There is no outstanding debt for AYLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -20.92, we must say that AYLA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of AYLA (-20.92) is worse than 90.14% of its industry peers.
There is no outstanding debt for AYLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.92
ROIC/WACCN/A
WACC8.99%

2.3 Liquidity

A Current Ratio of 2.28 indicates that AYLA has no problem at all paying its short term obligations.
AYLA's Current ratio of 2.28 is on the low side compared to the rest of the industry. AYLA is outperformed by 79.97% of its industry peers.
A Quick Ratio of 2.28 indicates that AYLA has no problem at all paying its short term obligations.
AYLA has a Quick ratio of 2.28. This is in the lower half of the industry: AYLA underperforms 77.93% of its industry peers.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.28

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.10% over the past year.
The Revenue for AYLA has decreased by -48.36% in the past year. This is quite bad
EPS 1Y (TTM)13.1%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q2.94%
Revenue 1Y (TTM)-48.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-85.44%

3.2 Future

AYLA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -8.08% yearly.
The Revenue is expected to decrease by -12.82% on average over the next years. This is quite bad
EPS Next Y3.59%
EPS Next 2Y8.3%
EPS Next 3Y-8.08%
EPS Next 5YN/A
Revenue Next Year-33.92%
Revenue Next 2Y-12.82%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AYLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AYLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as AYLA's earnings are expected to decrease with -8.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.3%
EPS Next 3Y-8.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AYLA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AYALA PHARMACEUTICALS INC

NASDAQ:AYLA (1/18/2023, 7:00:01 PM)

0.5036

+0.03 (+5.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.46M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 5.19%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.28
Quick Ratio 2.28
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)13.1%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y3.59%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-48.36%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y